Targeting cancer with click chemistry
Shasqi is a clinical-stage biotech using Nobel Prize-winning click chemistry to develop tumor-targeted cancer therapies. Its CAPAC platform uses pre-targeting to activate drugs selectively at the tumor, enabling higher doses with reduced systemic toxicity. The company has collaborations with Johnson & Johnson and NIH, and is advancing its lead asset SQ3370 through clinical trials.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNov 2021
Oct 2019
Jan 2015
Create a free account to see which investors have funded this company.
Create Free Account
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
